百令胶囊联合醋酸泼尼松对肾病综合征患者肾功能及脂质代谢紊乱的影响
|
摘要
目的探讨百令胶囊联合醋酸泼尼松对肾病综合征患者肾功能及脂质代谢紊乱的影响。方法按随机数字表法将2016年2月—2017年5月接诊的96例肾病综合征患者分为对照组和观察组,每组48例。对照组采用醋酸泼尼松治疗,观察组在此基础上给予百令胶囊。连续用药6个月后,比较两组肝功能[血尿素氮(BUN)、血浆白蛋白(ALB)、血肌酐(SCr)]、脂质代谢[高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、胆固醇(TC)]、24 h尿蛋白水平以及临床疗效。结果治疗后,两组BUN、ALB、SCr水平较治疗前具有显著改善(P<0.05),且观察组BUN、SCr水平低于对照组,ALB水平高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组HDL-C水平显著升高,LDL-C、TG、TC水平均显著降低(P<0.05);且观察组HDL-C水平高于对照组,LDL-C、TG、TC水平均低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组24 h尿蛋白水平均明显下降(P<0.05),且观察组24 h尿蛋白水平低于对照组,差异具有统计学意义(P<0.05)。观察组治疗总有效率为95.83%,明显高于对照组的81.25%,差异具有统计学意义(P<0.05)。结论对肾病综合征患者采用百令胶囊、醋酸泼尼松联合治疗,能改善肾功能和脂质代谢紊乱,降低24 h尿蛋白水平,提高临床疗效。
Objective To investigate the effect of Corbrin capsules combined with prednisone acetate on renal function and lipid metabolism disorder in patients with nephrotic syndrome(NS). Methods 96 NS patients admitted into our hospital from February2016 to May 2017 were divided into two groups by random number table, 48 cases in each group. Control group was given prednisone acetate, while experimental group was treated with Corbrin capsules based on control group. After six-month treatment,the liver function [blood urea nitrogen(BUN), albumin(ALB), serum creatinin(SCr)], lipid metabolism [ high-density lipoprotein cholesterol(HDL-C), triglyceride(TG), low-density lipoprotein cholesterol(LDL-C), total cholesterol(TC)], 24 h urinary protein level and clinical efficacy were compared between the two groups.Results The levels of BUN and SCr in experimental group were lower than those in control group, while the level of ALB was higher than control group(P < 0.05). The levels of TG, TC, LDL-C in experimental group were lower than those in control group, while the level of HDL-C was higher than control group(P < 0.05). The24 h urinary protein of experimental group [(1.46 ± 1.05) g/24 h] was lower than control group [(2.18 ± 1.22) g/24 h](P < 0.05). The total effective rate of experimental group(95.83%) was higher than control group(81.25%)(P < 0.05).Conclusion Corbrin capsules combined with prednisone acetate in treatment of NS can effectively improve renal function and lipid metabolism disorder, decrease the level of 24 h urinary protein and increase clinical efficacy.
Objective To investigate the effect of Corbrin capsules combined with prednisone acetate on renal function and lipid metabolism disorder in patients with nephrotic syndrome(NS). Methods 96 NS patients admitted into our hospital from February2016 to May 2017 were divided into two groups by random number table, 48 cases in each group. Control group was given prednisone acetate, while experimental group was treated with Corbrin capsules based on control group. After six-month treatment,the liver function [blood urea nitrogen(BUN), albumin(ALB), serum creatinin(SCr)], lipid metabolism [ high-density lipoprotein cholesterol(HDL-C), triglyceride(TG), low-density lipoprotein cholesterol(LDL-C), total cholesterol(TC)], 24 h urinary protein level and clinical efficacy were compared between the two groups.Results The levels of BUN and SCr in experimental group were lower than those in control group, while the level of ALB was higher than control group(P < 0.05). The levels of TG, TC, LDL-C in experimental group were lower than those in control group, while the level of HDL-C was higher than control group(P < 0.05). The24 h urinary protein of experimental group [(1.46 ± 1.05) g/24 h] was lower than control group [(2.18 ± 1.22) g/24 h](P < 0.05). The total effective rate of experimental group(95.83%) was higher than control group(81.25%)(P < 0.05).Conclusion Corbrin capsules combined with prednisone acetate in treatment of NS can effectively improve renal function and lipid metabolism disorder, decrease the level of 24 h urinary protein and increase clinical efficacy.
引文
[1] Chen Y, Wan J X, Jiang D W, et al. Efficacy of calcitriol in treating glucocorticoidinduced osteoporosis in patients with nephrotic syndrome:an open-label, randomized controlled study[J]. CN, 2015, 84(2015)(11):262-269.
[2]阳源.不同剂量低分子肝素联合他汀类药物治疗肾病综合征患者的效果比较[J].医疗装备, 2017, 30(14):124-125.
[3]张玲,赵向阳,李鹏飞,等.醋酸泼尼松联合地黄叶总苷胶囊治疗肾病综合征疗效观察[J].中国中西医结合肾病杂志, 2017, 18(2):150.
[4]汤娜.百令胶囊在妊娠期肾病综合征患者中的应用及对母婴结局的影响[J].中国妇幼保健, 2017, 32(11):2297-2300.
[5]陈灏珠,林果为,王吉耀.实用内科学[M]. 14版.北京:人民卫生出版社, 2013.
[6]叶任高,陈裕盛,方敬爱.肾脏病诊断与治疗及疗效标准专题讨论纪要[J].中国中西医结合肾病杂志, 2003, 4(6):355-357.
[7] Kamei K, Ogura M, Sato M, et al. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab[J]. Pediatr Nephrol,2016, 31(1):89-95.
[8]杨蓉.黄芪注射液联合赖诺普利胶囊和醋酸泼尼松片治疗急性肾病综合征的临床研究[J].中国临床药理学杂志, 2016, 32(20):1852-1855.
[9]支亚军.自拟益肾固元汤结合醋酸泼尼松片治疗肾病综合征临床研究[J].国际中医中药杂志, 2016, 38(11):978-981
[10]程玉婷,张雅兰,吴垚,等.狼疮性肾炎的中西医结合治疗进展[J].中国中西医结合肾病杂志, 2017, 18(3):278-280.
[11]杨靖.黄葵胶囊联合百令胶囊治疗早期糖尿病肾病蛋白尿临床观察[J].中国医药导刊, 2017, 19(7):717, 719.
[12] Liu X, Zhong F, Tang X L, et al. Cordyceps sinensis protects against liver and heart injuries in a rat model of chronic kidney disease:a metabolomic analysis[J]. Acta Pharmacol Sin, 2014, 35(5):697-706.
[13]马西臣,彭君,谭玉利,等.百令胶囊对慢性肾脏病患者相关炎性因子的影响[J].中国基层医药, 2017, 24(21):3242-3245.
[14] Chang Y, Hsu W H, Lu W J, et al. Inhibitory mechanisms of CME-1, a novel polysaccharide from the mycelia of cordyceps sinensis, in platelet activation[J]. CPB, 2015,16(5):451-461.
[15]刘泽辉,张亚同,胡欣,等.百令胶囊治疗慢性肾衰有效性系统评价[J].临床药物治疗杂志, 2017, 15(2):37-42.
[2]阳源.不同剂量低分子肝素联合他汀类药物治疗肾病综合征患者的效果比较[J].医疗装备, 2017, 30(14):124-125.
[3]张玲,赵向阳,李鹏飞,等.醋酸泼尼松联合地黄叶总苷胶囊治疗肾病综合征疗效观察[J].中国中西医结合肾病杂志, 2017, 18(2):150.
[4]汤娜.百令胶囊在妊娠期肾病综合征患者中的应用及对母婴结局的影响[J].中国妇幼保健, 2017, 32(11):2297-2300.
[5]陈灏珠,林果为,王吉耀.实用内科学[M]. 14版.北京:人民卫生出版社, 2013.
[6]叶任高,陈裕盛,方敬爱.肾脏病诊断与治疗及疗效标准专题讨论纪要[J].中国中西医结合肾病杂志, 2003, 4(6):355-357.
[7] Kamei K, Ogura M, Sato M, et al. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab[J]. Pediatr Nephrol,2016, 31(1):89-95.
[8]杨蓉.黄芪注射液联合赖诺普利胶囊和醋酸泼尼松片治疗急性肾病综合征的临床研究[J].中国临床药理学杂志, 2016, 32(20):1852-1855.
[9]支亚军.自拟益肾固元汤结合醋酸泼尼松片治疗肾病综合征临床研究[J].国际中医中药杂志, 2016, 38(11):978-981
[10]程玉婷,张雅兰,吴垚,等.狼疮性肾炎的中西医结合治疗进展[J].中国中西医结合肾病杂志, 2017, 18(3):278-280.
[11]杨靖.黄葵胶囊联合百令胶囊治疗早期糖尿病肾病蛋白尿临床观察[J].中国医药导刊, 2017, 19(7):717, 719.
[12] Liu X, Zhong F, Tang X L, et al. Cordyceps sinensis protects against liver and heart injuries in a rat model of chronic kidney disease:a metabolomic analysis[J]. Acta Pharmacol Sin, 2014, 35(5):697-706.
[13]马西臣,彭君,谭玉利,等.百令胶囊对慢性肾脏病患者相关炎性因子的影响[J].中国基层医药, 2017, 24(21):3242-3245.
[14] Chang Y, Hsu W H, Lu W J, et al. Inhibitory mechanisms of CME-1, a novel polysaccharide from the mycelia of cordyceps sinensis, in platelet activation[J]. CPB, 2015,16(5):451-461.
[15]刘泽辉,张亚同,胡欣,等.百令胶囊治疗慢性肾衰有效性系统评价[J].临床药物治疗杂志, 2017, 15(2):37-42.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |